Equities
Health CareMedical Equipment and Services
  • Price (USD)426.11
  • Today's Change-11.19 / -2.56%
  • Shares traded91.00
  • 1 Year change-0.61%
  • Beta1.3749
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. Its Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. Its LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve the quality and safety of milk.

  • Revenue in USD (TTM)3.84bn
  • Net income in USD866.24m
  • Incorporated1983
  • Employees11.00k
  • Location
    IDEXX Laboratories IncOne Idexx DriveWESTBROOK 04092-2041United StatesUSA
  • Phone+1 (207) 556-0300
  • Fax+1 (207) 556-4346
  • Websitehttps://www.idexx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cooper Companies Inc3.80bn359.30m20.31bn15.00k56.802.5627.605.341.801.8019.0239.800.31961.705.56253,606.703.0210.063.2911.3466.3665.549.4529.001.185.460.24930.34698.617.24-23.74-3.6615.180.00
Zimmer Biomet Holdings Inc7.60bn1.08bn21.89bn18.00k20.941.7710.632.885.255.2536.8762.000.35380.91365.38421,972.205.052.215.822.5271.7871.2514.287.280.69877.520.342538.906.55-1.40252.86--9.440.00
Steris PLC5.12bn602.62m21.96bn18.18k36.663.3319.834.296.084.3851.6266.800.47583.865.49281,655.405.625.196.105.6843.0143.6411.8110.971.558.290.252836.5613.2813.06-1.0712.6713.698.83
Waters Corp2.91bn622.64m22.91bn7.90k36.8114.2928.127.8810.4810.4848.8927.000.6452.204.47367,740.1013.8219.7716.7225.2959.7358.4521.4323.381.3810.110.53250.00-0.52294.09-9.261.534.72--
Illumina Inc4.39bn-1.58bn23.41bn10.59k--11.05--5.33-10.00-10.0027.6113.360.54412.666.17414,542.00-19.63-6.20-23.16-7.2863.9466.39-36.08-15.481.8538.440.4834---1.756.2173.64---7.91--
West Pharmaceutical Services Inc.2.88bn499.60m23.73bn10.60k48.558.6337.428.256.756.7538.8637.960.77434.505.51271,358.5013.0215.6115.1618.6534.8738.0616.8118.472.23--0.069510.692.1811.432.2823.7628.166.20
DexCom Inc3.95bn680.80m29.04bn9.60k45.3814.6732.517.341.641.649.525.070.61072.764.42411,875.0010.518.3014.2810.5062.1065.9017.2214.142.12--0.55790.0024.4928.5658.70--28.66--
IDEXX Laboratories, Inc.3.84bn866.24m34.89bn11.00k41.1121.6035.179.0810.3610.3646.0019.721.193.857.14349,528.8026.9128.0038.8643.4960.7258.7422.5321.351.0359.100.35070.008.7210.5924.4417.391.68--
Resmed Inc4.81bn1.11bn36.29bn9.98k32.776.9828.147.557.547.5432.5935.390.68862.176.08481,711.9015.9414.2418.1116.5357.6756.8523.1520.351.9144.710.115432.6210.9512.4413.7519.988.235.34
Veeva Systems Inc2.57bn615.26m38.30bn7.17k61.377.3858.7614.883.853.8515.6932.040.4453--6.27358,846.8010.6511.9712.9715.3673.3572.0023.9123.74----0.000.009.6822.357.7918.0021.68--
Agilent Technologies Inc6.50bn1.41bn38.41bn17.40k27.806.5123.105.914.814.8122.1420.530.59962.875.06358,950.3013.0411.0016.1313.2554.7553.2921.7518.011.3755.860.331921.46-0.2196.82-1.127.3910.988.86
GE HealthCare Technologies Inc19.56bn1.68bn38.80bn51.00k23.264.6616.771.983.653.6542.6318.200.59065.404.41383,490.205.22--6.97--41.33--8.84--0.9825.670.5478--6.60---26.82------
Edwards Lifesciences Corp5.62bn1.43bn38.81bn19.80k27.794.0724.856.902.376.939.3216.180.50321.127.72283,904.0012.7616.6314.9819.1278.6376.7125.3524.842.89--0.05850.0011.5610.03-7.8513.701.96--
Cencora Inc293.96bn1.51bn49.02bn42.00k33.1562.3118.600.16687.517.511,467.703.994.5315.5912.44--2.341.1211.514.833.353.250.51680.25560.529119.370.84865.3812.1210.36-13.5313.029.454.98
Data as of Nov 12 2024. Currency figures normalised to IDEXX Laboratories Inc's reporting currency: US Dollar USD

Institutional shareholders

40.48%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 20249.70m11.79%
BlackRock Fund Advisorsas of 30 Jun 20245.56m6.76%
SSgA Funds Management, Inc.as of 30 Jun 20243.63m4.41%
Fundsmith LLPas of 30 Jun 20243.53m4.28%
AllianceBernstein LPas of 30 Jun 20243.14m3.82%
Geode Capital Management LLCas of 30 Jun 20242.22m2.70%
BAMCO, Inc.as of 30 Jun 20242.04m2.47%
William Blair Investment Management LLCas of 30 Sep 20241.23m1.49%
T. Rowe Price Associates, Inc. (IM)as of 30 Jun 20241.15m1.40%
Brown Advisory LLCas of 30 Jun 20241.12m1.36%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.